Effective March 1, 2024, EmblemHealth and ConnectiCare will align with CMS on which drugs and biologics are considered routine under facility, surgical, and room and board charges and which drugs will be reimbursed separately. The plan will follow the CMS status of pass-through payments or separately reimbursed payments as detailed in our new Drugs and Biologicals Reimbursement Policy.
JP 63744 11/2023